ICAM1 and neoplasm: Researchers found that TNBC cells release ICAM1-enriched small EVs and the binding of ICAM1 to its receptor is necessary for the suppressive effect on CD8 + T cell activity, creating an immunosuppressive TME that may contribute to TNBC tumor growth and bone metastasis.